Phase 1 First-in-Human Clinical Trial Results With TRACON Pharmaceuticals, Inc. Antibodies TRC105 and TRC093 to be Presented At the 2008 AACR-NCI-EORTC Annual Meeting

SAN DIEGO, Oct. 14, 2008 (GLOBE NEWSWIRE) -- Tracon Pharmaceuticals, Inc., a biopharmaceuticals company focused on the development of products for oncology and ophthalmology treatment, including agents that inhibit angiogenesis, announced today that Phase 1 clinical trial results with monoclonal antibodies TRC093 and TRC105 will be presented at the 20th European Organization for Research and Treatment of Cancer (EORTC) -- National Cancer Institute (NCI) -- American Association for Cancer Research (AACR) symposium on 'Molecular Targets and Cancer Therapeutics' in Geneva, Switzerland.